noom clinical glp-1 Launches Free Version of Its Powerful Companion Noom Debuts Microdose GLP-1 Program
Description
Although private insurers in Denmark have historically reimbursed Wegovy, they will stop in January 2024 due to high demand [22,23]
Since its not yet FDA approved, we dont have a full risk profile of orforglipron
For most appropriately selected patients, the benefits outweigh the risks
Both can lead to muscle loss if weight is lost too rapidly
